Evidence map›Paper›PMID 33659549›Full record

ArticleBio-protocol2020

Lei Qi, Teresa Knifley, Dava W Piecoro, Piotr Rychahou, Jianrong Wu, Kathleen L O'Connor, Min Chen

Open access · bronzeAbstract read
In one paragraph

Article in Bio-protocol, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lei QiMarkey Cancer Center, University of Kentucky, Lexington, 40536-0679, USA.
Teresa KnifleyMarkey Cancer Center, University of Kentucky, Lexington, 40536-0679, USA.
Dava W PiecoroDepartment of Pathology and Laboratory Medicine, University of Kentucky, Lexington, 40536-0298, USA.
Piotr RychahouMarkey Cancer Center, University of Kentucky, Lexington, 40536-0679, USA.
Jianrong WuMarkey Cancer Center, University of Kentucky, Lexington, 40536-0679, USA.
Kathleen L O'ConnorMarkey Cancer Center, University of Kentucky, Lexington, 40536-0679, USA.
Min ChenMarkey Cancer Center, University of Kentucky, Lexington, 40536-0679, USA.
University of Kentucky · USMarkey Cancer Center · US

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI KATHLEEN L. O'CONNOR · 2013 to 2026
$38.3M
Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
University of Kentucky Center for Cancer MetabolismP20GM121327 · NIGMS · UNIVERSITY OF KENTUCKY · PI Binhua P Zhou · 2017 to 2026
$25.0M
Kentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3M
Novel Mechanisms of Carcinoma Cell MigrationR01CA109136 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI O'CONNOR, KATHLEEN L. · 2006 to 2016
$2.6M
Integrin alpha6beta4 regulation of cancer epigeneticsR01CA223164 · NCI · UNIVERSITY OF KENTUCKY · PI O'CONNOR, KATHLEEN L. · 2019 to 2023
$2.3M
NCATS NIH HHS UL1 TR000117NCATS NIH HHS UL1 TR001998NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA109136NCI NIH HHS R01 CA223164NIGMS NIH HHS P20 GM121327
6 · The paper itself

Abstract

Metastasis accounts for the majority of cancer related deaths. The genetically engineered mouse (GEM) models and cell line-based subcutaneous and orthotopic mouse xenografts have been developed to study the metastatic process. By using lung cancer cell line A549 as an example, we present a modified protocol to establish the cell line-based xenograft. Our protocol ensures sufficient establishment of the mouse xenografts and allows us to monitor tumor growth and spontaneous metastasis. This protocol could be adapted to other types of established cancer cell lines or primary cancer cells to study the mechanism of metastatic process as well as to test the effect of the potential anti-cancer agents on tumor growth and metastatic capacity.

Indexed as

Cell line xenograftImplantationMetastasis rateMousePatient-derived xenograftTumor growth

Identifiers

PMID33659549
PMCPMC7842773
OpenAlexW3014927388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.